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OBJECTIVE — In patients with long-standing type 1 diabetes, we investigated whether im-
proved -cell function can be achieved by combining intensive insulin therapy with agents that
may 1) promote -cell growth and/or limit -cell apoptosis and 2) weaken the anti–-cell
autoimmunity.
RESEARCH DESIGN AND METHODS — For this study, 20 individuals (mean age
39.5  11.1 years) with long-standing type 1 diabetes (21.3  10.7 years) were enrolled in this
prospectiveopen-labelcrossovertrial.Afterachievingoptimalbloodglucosecontrol,16subjects
wererandomizedtoexenatidewithorwithoutdaclizumab.Endogenousinsulinproductionwas
determined by repeatedly measuring serum C-peptide.
RESULTS — In 85% of individuals with long-standing type 1 diabetes who were screened for
participation in this trial, C-peptide levels 0.05 ng/ml (0.02 nmol/l) were found. Residual
-cellsrespondedtophysiological(mixed-meal)andpharmacological(arginine)stimuli.During
exenatide treatment, patients lost 4.1  2.9 kg body wt and insulin requirements declined
signiﬁcantly (total daily dose on exenatide 0.48  0.11 vs. 0.55  0.13 units   kg
1   day
1
without exenatide; P  0.0062). No signs of further activation of the underlying autoimmune
disease were observed. Exenatide delayed gastric emptying, suppressed endogenous incretin
levels, but did not increase C-peptide secretion.
CONCLUSIONS — In long-standing type 1 diabetes, which remains an active autoimmune
disease even decades after its onset, surviving -cells secrete insulin in a physiologically regu-
lated manner. However, the combination of intensiﬁed insulin therapy, exenatide, and dacli-
zumab did not induce improved function of these remaining -cells.
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I
n the past 2 decades, several lines of
research dominated the ﬁeld of type 1
diabetes: trials to alter the immunolog-
ical response against -cells and attempts
to develop and replace -cells. The latter,
represented by islet transplantation in the
clinical arena, has led to the realization
that lasting insulin independence could
not be achieved (1), but progress was
made by gaining insight into -cell devel-
opment (2–4) and immunomodulation.
Experimental therapies such as adminis-
tration of the monoclonal antibody anti-
CD3 and the -cell antigen GAD65
slowed -cell destruction when adminis-
tered soon after disease onset (5,6). Cur-
rently, however, no therapy is available
that results in a complete halt or reversal
of -cell failure.
We initiated this trial in patients with
well-controlled long-standing type 1 dia-
betes who had evidence of endogenous
insulin production documented by mea-
surable C-peptide concentrations 0.3
ng/ml (0.1 nmol/l). The study partici-
pants received exenatide, a glucagon-like
peptide (GLP)-1 agonist, to stimulate
-cell recovery and possibly regeneration
(7,8); 50% of patients also received dacli-
zumab to diminish the underlying auto-
immunity and to curb a potential
autoimmune reactivation. -Cell func-
tion was repeatedly assessed by measur-
ing basal and stimulated C-peptide
concentrations (9). We speculated that
thedifferencebetweengreater-cellmass
and improved function could be deter-
mined by observing the duration of any
treatment effect; i.e., if the intervention
resulted in increased -cell mass, im-
proved pancreatic insulin production
would be expected to persist beyond the
exenatide treatment. Daclizumab was
chosen as a mild immunosuppressive
agent because of its safety proﬁle and its
demonstrated efﬁcacy in other T-cell–
mediatedautoimmuneconditionssuchas
uveitis and multiple sclerosis (10,11).
RESEARCH DESIGN AND
METHODS— Individuals with type 1
diabetes who contacted the National In-
stitutesofHealth(NIH)recruitmentofﬁce
were asked to complete a questionnaire.
At the NIH clinical center, 47 patients
were selected for testing and 20 were en-
rolled (Table 1; Fig. 1). Inclusion criteria
were 1) age 18–60 years, 2) C-peptide
0.3 ng/ml (0.1 nmol/l) at baseline or
after arginine stimulation, 3) positive an-
tibodies (GAD65, ICA-512) and/or a typ-
ical history of type 1 diabetes, 4) duration
of disease 5 years, and 5) BMI 20–30
kg/m
2. Exclusion criteria were gastropa-
resis, diabetic nephropathy, insulin re-
quirement 0.8 units   kg
1   day
1, and
hypoglycemia unawareness. To deter-
mine reference values, we performed
mixed-meal testing in three healthy indi-
viduals (all female, mean age 33.3  11.1
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2). This study
(NCT00064714)wasapprovedbythein-
stitutional review board of the National
Institute of Diabetes and Digestive and
Kidney Diseases. All patients provided
written informed consent.
Study design
The study followed a prospective ran-
domized open-label crossover design
(Fig. 1). It consisted of an optimization
period of 2–4 months during which the
NIH study team improved the patients’
glucose control. Patients then entered the
run-in period, a 4-month period during
which no major changes in diabetes man-
agement were made. At screening and
during the run-in period, patients under-
went a total of four arginine stimulation
tests and two mixed-meal tests to deter-
mine baseline C-peptide secretion (Fig.
1B). Thereafter, subjects were random-
izedtooneoffourtreatmentarms(insulin
only, insulin plus exenatide, insulin plus
exenatide plus daclizumab, or insulin
plus daclizumab). After 6 months (period
A), patients treated with exenatide dis-
continueditsadministration,whereaspa-
tients not previously treated with
exenatide initiated it. The treatment as-
signmentregardingdaclizumabremained
unchanged during this second 6-month
interval (period B). In both periods A and
B,threeargininestimulationtestsandone
mixed-meal test were performed. Finally,
enrollees entered a 3-month extension
period, in which they continued the as-
signed treatment of period B. Special at-
tention was paid to prevent or treat
vitamin D deﬁciency, hyperlipidemia,
and hypertension.
Exenatide (Byetta; Amylin, San Di-
ego, CA) was administered subcutane-
ously via a noncommercial pen that
allowed dose adjustments in 2.5-g in-
crements. Dose and frequency were
gradually increased from 2.5 g twice
daily to 10 g four times daily. At the
onset of exenatide therapy, insulin bo-
lus doses were reduced by 50%,
whereas basal insulin (for insulin pump
users)andlong-actinginsulindoses(for
multiple–daily injection users) re-
mained unchanged. Insulin bolus doses
were gradually titrated upward accord-
ingtobloodglucosevalues.Daclizumab
(Zenapax; Roche, Nutley, NJ) was in-
fused intravenously at 2 mg/kg over 30
min once monthly.
Arginine and mixed-meal tests were
performed after an overnight fast. With
pretest blood glucose levels of 150
mg/dl (8.3 nmol/l), two intravenous lines
wereplaced.Baselinebloodsampleswere
obtained at 10 and 0 min before intra-
venous infusion of 5 g arginine (10% so-
lution). Samples were collected from the
contralateral cephalic vein at 2, 3, 4, 5, 7,
9, and 10 min and immediately placed on
ice until centrifuged at 2,000 rpm for 10
min at 4°C. Samples were then aliquoted
and frozen at 20°C.
Mixed-meal tests were performed 30
min after the arginine stimulation tests.
Patients assigned to exenatide received
medication 15 min prior to testing. Blood
samples were obtained at 10, 0, 15, 30,
45, 60, 90, 120, 150, 180, and 240 min.
At time point 0 min, patients consumed
Boost High Protein (7 ml/kg body wt,
maximally 400 ml) in 10 min. Blood
samples were processed and stored as de-
scribed above.
Table 1—Clinical and immunological characteristics of the 20 enrolled patients at screening
No. Sex
BMI
(kg/m
2)
Duration of
disease
(years) A1C (%)
Basal (stim)
C-peptide
(ng/ml)
Antibodies HLA haplotypes T-cell reactivity
ICA512 GAD65 DRB1 DQB1
Toronto
(no. of 
antigens)
Seattle
(no. of 
sections)
1 F 24.3 10.2 7.6 0.70 (1.00) neg pos 0301, 1601 0201, 0502 40
2 F 27.1 22.0 6.2 0.75 (0.80) pos pos 0404, 0404* 0302, 0302* 9N R
3 F 21.0 6.3 8.4 0.75 (1.00) pos pos 0301, 0401 0201, 0302 91 8
4 M 29.1 21.0 8.0 0.93 (1.10) neg pos 0301, 0401 0201, 0302 4N R
5 F 30.9 16.8 6.5 0.57 (0.80) pos neg 0401, 0402 0302, 0302* 51 2
6 M 23.8 38.4 7.1 0.20 (0.50) neg neg 0301, 0405 0201, 0302 0N R
7 F 21.7 22.5 7.4 0.39 (0.60) neg neg 0301, 0301* 0201, 0201* 35
8 M 22.6 25.6 7.5 0.58 (0.89) neg neg 0405, 0405* 0302, 0302* 10 4
9 F 31.2 16.8 7.1 0.44 (0.62) neg pos 0301, 0405 0201, 0302 10 5
10 M 24.7 5.9 5.9 0.63 (0.94) neg pos 0102, 1501 0501, 0602 6N R
11 M 24.6 24.0 7.9 0.15 (0.62) neg neg 0404, 1104 0302, 0301 12 9
12 M 29.8 36.1 5.6 0.22 (0.36) neg pos 0301†, 0401 0201, 0302 10 NR
13 M 27.1 37.1 7.0 0.76 (1.10) neg pos 0301†, 0301† 0201, 0201 11 0
14 F 30.0 4.1 7.0 0.60 (0.91) pos pos 0401, 1302 0301, 0604 11 NR
15 M 27.4 12.4 6.8 1.20 (1.80) neg pos 0301, 1601 0201, 0502 11 4
16 F 27.5 30.4 8.9 0.27 (0.42) neg pos 0401, 0701 0202, 0302 90
17 F 20.1 33.4 8.1 0.54 (0.68) neg pos 0301, 0401 0201, 0302 NR NR
18 M 26.1 29.8 10.2 0.62 (0.72) neg neg 0301, 1501 0201, 0602 NR NR
19 F 27.9 11.7 5.7 0.36 (0.56) pos pos 0408, 1104 0304, 0603 NR NR
20 F 22.0 21.4 6.8 0.48 (0.68) pos pos 0101, 0401 0302, 0501 NR NR
9M/11F 25.9  3.4 21.3  10.7 7.3  1.1 0.57 (0.81) 6 of 20 14 of 20 See legend See legend 14 of 16 7 of 10
Patients 1–16 were randomized to one of four study arms and patients 1–14 completed the trial. Of the patients, 16 of 20 had high-susceptibility HLA haplotypes;
1 had a mixed and 1 a protective haplotype (indicated in bold print). *Homozygosity is highly likely but could only be proven by family studies, which were not
available; †HLA type could not be differentiated with certainty (0301 vs. 0328); underlined numbers indicate that the haplotype belongs to one of ﬁve most
susceptible subtypes (25). neg, negative; NR, no results available; pos, positive.
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C-peptide was determined with a solid-
phase, two-site immunochemilumines-
cent assay (Esoterix, lower limit of
detection 0.05 ng/ml [0.02 nmol/l]).
Cross-reactivitywithinsulinwas0.01%
at 100 and 200 U/ml human insulin.
The glucose oxidase method was used for
serum glucose measurements. A1C was
determined by high-performance liquid
chromatography (normal 4.8–6.4%).
Glucagon was measured using a double-
antibody radioimmunoassay (Esoterix,
lower limit of detection 10 pg/ml). Acet-
aminophen was determined by a particle-
enhanced turbidimetric inhibition
immunoassay with the analytical range
10–300 g/ml (lowest detectable dose
2.5 g/ml). Total GLP-1 was measured
with a radioimmunoassay (Millipore,
lower limit of detection 3.0 pmol/l).
T-cell assays were performed at three
time points (Fig. 1B) in two different lab-
oratories (M. Dosch, Toronto, Canada;
and B. Brooks-Worrell and J. Palmer, Se-
attle, WA) (12). At both sites, T-cell pro-
liferation in response to diabetes-related
antigens was determined by direct
3H-
thymidine incorporation. Samples were
labeledaspositiveforautoimmunityifthe
T-cells proliferated to 3 (Toronto) or
4(Seattle)ofthetestantigenscompared
with responses against unspeciﬁc control
antigens. The Toronto laboratory used a
panel of 12 predeﬁned diabetes-related
peptide or protein antigens and included
exogenous interleukin-2 in the assay me-
dium. The Seattle laboratory used mix-
tures of antigen eluted from gel-
fractionated human islet cell proteins
with 18 size fractions separated by SDS
polyacrylamidegel.HLAhaplotypeswere
determined using sequence-speciﬁc
primers at the Department of Transfusion
Medicine at the NIH Clinical Center.
Figure 1—Study design (A) and timeline for testing procedures (B): 20 patients entered the optimization period, 16 were randomized, and 14
completed the entire trial. B: A, arginine stimulation test; M, mixed-meal test; T, T-cell proliferation test.
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Sample size calculations were based on
data from 1) NIH patients having under-
gone islet transplantation with no C-
peptide before transplantation but
measurable C-peptide after transplanta-
tion and 2) data on the variability of indi-
vidual patient values in periods similar to
the run-in period of this study. Sample
size estimates were designed to detect a
50% increase of C-peptide levels on ex-
enatide treatment, resulting in a sample
size estimate of 12 patients.
Primary outcome measures were
basedonbasal(10and0min)andstim-
ulated (single highest value during test
procedure) C-peptide levels. These were
measured monthly before and during ar-
ginine stimulation during the last 3
months of each treatment period (Fig.
1B). C-peptide values were averaged
across these three time points. Because
50%ofpatientsalsoreceiveddaclizumab,
two-way analyses of variance (ANOVAs)
were run to assess daclizumab treatment
and its possible interaction with ex-
enatide: daclizumab usage was a second
factor and the period-sequence by dacli-
zumabinteractiontermwasincluded.Be-
causethePvaluesfortheinteractionterm
were highly nonsigniﬁcant (basal P 
0.74; stimulated P  0.81), as were the P
values for the overall effect of daclizumab
(basalP0.87;stimulatedP0.84),the
daclizumab and no-daclizumab groups
were combined in the main analyses of
exenatide. To eliminate confounding due
to a possible period effect (e.g., due to
prolonged intensive insulin treatment),
the test based on the two-sample t ap-
proachwasused(13).Two-sidedPvalues
0.05 were considered signiﬁcant and
results were presented as means  SD if
not indicated otherwise.
RESULTS— Patientcharacteristicsare
shown in Table 1. The 9 male and 11 fe-
male Caucasian patients (mean age
39.5  11.1 years) had type 1 diabetes
duration of 21.3  10.7 years. At screen-
ing, A1C was 7.3  1.1% (range 5.6–
10.2%). Patients used multiple daily
injections (MDI, n  7) or continuous
subcutaneous insulin infusions (insulin
pump, n  13). Four patients were anti-
body negative but had a typical history of
type 1 diabetes with childhood onset
and/or positive family history and high-
risk HLA haplotypes (Table 1). Only pa-
tients 10 and 18 had mixed or entirely
protective HLA haplotypes, which may
explain their presentation at an older age.
C-peptide secretion
Of 47 subjects who underwent detailed
screeningprocedures,40completedboth
arginine stimulation and mixed-meal
tests: 55% had measurable C-peptide in
bothtests,12.5%onlyafterargininestim-
ulation, and 17.5% only in the mixed-
meal test. Thus, 85% had detectable
C-peptide 0.05 ng/ml (0.02 nmol/l) in
two common stimulation tests.
Once intensiﬁed glucose manage-
ment began (but before introduction of
exenatide and daclizumab), 4 patients
(patients 17–20) discontinued their par-
ticipation due to fear of hypoglycemia or
psychosocial problems. In the remaining
14 patients, A1C decreased from 7.2 
0.9% at screening to 6.5  0.7% at the
end of the run-in period (P  0.0003).
The pharmacological (arginine) and
physiological (mixed-meal) stimulation
of C-peptide was reduced by intensiﬁed
insulin treatment (Fig. 2A) during the
run-in period. All patients secreted less
C-peptidecomparedtotheirscreeningre-
sults(P0.0001forbasalandstimulated
C-peptide),and11patients(69%)hadno
detectableC-peptideintheirﬁrstarginine
stimulation test in this study period.
C-peptide secretion was insigniﬁ-
cantly higher during exenatide treatment,
and the addition of daclizumab did not
change this outcome (Fig. 2B). Mean
basal C-peptide levels were 0.029 ng/ml
(0.01 nmol/l) higher on exenatide versus
off exenatide (95% CI 0.058 to 0.115
ng/ml, P  0.48), and stimulated C-
peptide levels were 0.024 ng/ml (0.008
nmol/l) higher on exenatide (95% CI
0.090 to 0.138 ng/ml, P  0.66). Fur-
ther, there was no difference when ana-
lyzing C-peptide secretion depending on
the study period when exenatide was ad-
ministered. These results remained un-
changed when taking into account data
from the 3-month extension period.
Weight loss, insulin doses, and
glucose control
All but one patient (patient 13) lost
weight during the 6-month period on ex-
enatide (74.2  12.6 vs. 78.4  12.1 kg
on vs. off exenatide, respectively; P 
0.0003).Theobservedweightlossranged
between 1.1 and 8.8 kg (mean 4.1  2.9
kg).Themagnitudeofweightlossdidnot
correlate with the frequency of reported
nausea. Exenatide was well tolerated, and
patients simply described diminished ap-
petite. Glucose control did not change as
reﬂected by similar A1C values (6.51 
0.56 vs. 6.64  0.64% on vs. off ex-
enatide,respectively;P0.39),butinsu-
Figure 2—Results of C-peptide responses to arginine stimulation (A and B) and changes of insulin doses and weight according to treatment
assignment (C). C-peptide results are shown at screening (basal versus stimulated C-peptide, P  0.0001) and during run-in period (tests were
conducted in months 2, 3, and 4 of run-in period [basal versus stimulated C-peptide, P  0.0078]) (A) after 6 months of exenatide therapy versus
nothavingreceivedexenatide(irrespectiveofassignmenttodaclizumab)(B)withreferencetomeanresultsofrun-inperiod.DataaremeansSEM.
To convert C-peptide from conventional (ng/ml) to Si units (nmol/l), multiply by factor 0.333.
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dose 0.48  0.11 vs. 0.55  0.13 units  
kg
1   day
1 on vs. off exenatide, respec-
tively; P  0.0062). This reduction was
caused by 30% lower preprandial insulin
doses (short-acting insulin doses 0.18 
0.05 vs. 0.25  0.09 units   kg
1   day
1
on vs. off exenatide, respectively; P 
0.0056). Irrespective of exenatide treat-
ment, episodes of hypoglycemia (deﬁned
asglucosevalues55mg/dl[3.0nmol/l])
were rare (1.21  1.72 vs. 0.93  1.21
episodes per week on vs. off exenatide,
respectively; P  0.45).
Gastric emptying, glucagon, and
GLP-1
Exenatidedelayedgastricemptyingasde-
termined by acetaminophen absorption
(Fig. 3A). Glucose absorption was simi-
larly delayed (Fig. 3B). Fasting glucagon
levels remained unchanged whether pa-
tients received exenatide or not and were
indistinguishable from those of normal
control subjects. In contrast to results
from patients with type 2 diabetes, meal-
stimulated glucagon levels were not sup-
pressed by exenatide, with neither area
under the curve nor peak levels being dif-
ferent according to treatment status. In
contrast, exenatide suppressed endoge-
nous GLP-1 levels (Fig. 3D).
T-cell reactivity
The Toronto laboratory returned com-
plete results for all 44 samples shipped to
the laboratory, whereas the Seattle labo-
ratory returned complete results for 28 of
44 samples due to problems with sample
viability or high or low background pro-
liferation (Table 1). All subjects tested
positivefordiabetes-relatedT-cellautore-
activityinoneorbothoftheassaysusedat
one or more time points. Using the To-
ronto assay, 13 of 16 subjects were con-
sistently positive, whereas only 1 subject
was consistently negative, and that sub-
ject tested positive by the Seattle assay.
The Seattle assay was more variable, but
the majority (16 of 28) of tests was con-
cordant with the Toronto result.
CONCLUSIONS— This clinical trial
was based on the observation that some
endogenous insulin secretion may persist
in long-standing type 1 diabetes (14) and
on the assumption that such function
might recover (15). Our data and results
from other investigators support the no-
tion that residual -cells either avoid au-
toimmune-mediated cell death and/or
thatnew-cellsaregeneratedthroughout
life (16). We were able to document that
thesurviving-cellsnotonlycontributea
minimalamountofinsulinbutrespondto
various stimuli with prompt insulin
release.
Several studies suggest that -cell
survival is mostly limited by the ever-
vigilant autoimmunity (17). Our results
conﬁrmed diabetes-associated T-cell re-
activityinalmostallsubjectsevenafterup
to 3 decades of disease duration. Few
studies of T-cell autoimmunity have been
performed in long-standing diabetes, and
in particular there are no blinded con-
trolled studies distinguishing people with
diabetesfromcontrolsubjects.Ithasbeen
shown that pancreatic-draining lymph
nodes harbor many insulin-reactive
T-cells in subjects with long-standing
type 1 diabetes compared with healthy
control subjects (18). Because the T-cell
assays in our study were performed at the
Figure 3—Results of mixed-meal testing, conducted according to study timeline (Fig. 1B). Exenatide administered before a mixed meal delayed
gastric emptying (A; P  0.041) and glucose absorption (B; P  0.052), did not change glucagon levels (C; P  0.414), and suppressed GLP-1 (D;
P0.024).Pvaluesreﬂectdifferencesofareasunderthecurvecomparingpatients’resultsonandoffexenatide;dataaremeansSEM.Toconvert
glucose from conventional (mg/dl) to Si units (nmol/l), multiply by factor 0.0555.
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glucose control may have induced -cell
quiescence, protecting -cells from im-
mune killing and thereby promoting au-
toreactive T-cells to trafﬁc out of the
pancreatic-draining lymph nodes and
into the bloodstream.
Although our present results do not
support the original hypothesis that near-
normalglycemia,incombinationwithex-
enatide and daclizumab, can induce
clinically relevant -cell recovery, it can-
not be ruled out that other interventions
might. Indeed, plausible explanations ex-
ist for our negative ﬁndings, including
minimal residual -cell mass associated
with advanced patient age and prolonged
duration of disease as well as insufﬁcient
immunosuppression (19,20). Another
factor might have been excellent glucose
control because animal studies suggest
hyperglycemia may be necessary to pro-
mote -cell proliferation (21). Further-
more, recent studies have questioned
exenatide’s ability to promote -cell pro-
liferation (22,23). Although our results
are based on data from 14 patients taking
exenatide for 6–9 months, it is important
to note that this crossover study has the
equivalentpowertoaparallelgroupstudy
with 56 patients (28 patients in each
group, intervention and control). Thus,
thesamplesizeissmallbutcomparableto
other relevant studies in the ﬁeld. Fur-
thermore, looking at only the possible
positiveeffectofexenatide,ourdataallow
us to claim at a 97.5% level of conﬁdence
that the treatment caused 0.115 ng/ml
improvement in basal C-peptide secre-
tion,whichwedidnotregardasclinically
relevant.
At the same time, important knowl-
edge about the natural history of -cell
function was gained. We found that the
majority of patients with long-standing
type 1 diabetes had surviving -cells,
which promptly responded to standard
physiologic and pharmacologic stimuli.
Furthermore, exogenous insulin dimin-
ished both basal and stimulated C-
peptide. This ﬁnding highlights the
importance of standardizing pretest con-
ditions such as ambient blood glucose
and exogenous insulin dosing when eval-
uating -cell function.
Of special clinical interest is the ex-
enatide-induced weight loss and reduc-
tion in insulin requirements without
increasedfrequencyofhypoglycemia.Ex-
enatide suppressed GLP-1 levels and de-
layed gastric emptying associated with
slower glucose absorption. In contrast to
the expected suppression of inappropri-
atelyelevatedglucagonlevels(24),wedid
not see reduced hyperglucagonemia with
exenatide.Wespeculatethatthisisdueto
the long-standing abnormal intra-islet
cross talk between 	- and -cells.
In conclusion, residual -cells may
play an important role as a potential
source of new -cells in future trials, es-
pecially in younger patients and at an ear-
lier stage of the disease. More
combination therapies that include im-
munomodulators with agents that im-
prove -cell function and growth are
needed to expand residual -cell mass to
a degree that individuals with type 1 dia-
betes may eventually become insulin
independent.
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